CytomX Therapeutics CTMX Noncash Lease Expense
Noncash Lease Expense at other companies
Other financials
Where this comes from
Reported directly by CytomX Therapeutics in its filing.
Tagged under the XBRL concept ctmx:NoncashLeaseExpense.
The official record: CytomX Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about CytomX Therapeutics's noncash lease expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is CytomX Therapeutics's noncash lease expense?
- CytomX Therapeutics (CTMX) reported noncash lease expense of -$1.13M in Q1 2026.
- How has CytomX Therapeutics's noncash lease expense changed year-over-year?
- CytomX Therapeutics's noncash lease expense decreased by 4.7% year-over-year, from -$1.08M to -$1.13M.
- What is the long-term trend for CytomX Therapeutics's noncash lease expense?
- Over 4 years (2021 to 2025), CytomX Therapeutics's noncash lease expense has grown at a 9.4% compound annual growth rate (CAGR), from -$3.13M to -$4.48M.
- What does noncash lease expense mean?
- This represents the non-cash portion of lease expenses recognized under accounting standards for right-of-use assets. It reflects the systematic recognition of lease costs that do not involve an immediate cash outflow during the period. Tracking this helps analysts distinguish between actual cash-based operating expenses and accounting-driven lease obligations.